Institution Directory

Clinical trials at Dana-Farber Cancer Institute

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1325

Shown on this page

Current sort

Live official records

Conditions: Malignant Neoplasm
Interventions: Patritumab Deruxtecan; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 17
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 14 more

Conditions: Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung, Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, External Beam Radiation Therapy, Ganitumab, Ifosfamide, Stereotactic Radiosurgery, Therapeutic Surgical Procedure, Vincristine, Vincristine Sulfate; Drug · Radiation · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 50 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 298
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 203 more

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib; Drug
Lead sponsor: American Society of Clinical Oncology; Other
Eligibility: 60 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 88
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 76 more

Conditions: Refractory Solid Tumors, Relapsed Solid Tumors, Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Rhabdomyosarcoma, Refractory Rhabdomyosarcoma
Interventions: PEEL-224, Vincristine, Temozolomide (TMZ); Drug
Lead sponsor: Theodore Laetsch; Other
Eligibility: 1 Year to 30 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Interventions: LY4584180, Rituximab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more

Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Interventions: Emavusertib, Ibrutinib; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Duarte, California • Santa Monica, California + 19 more

Conditions: Core Binding Factor Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Gemtuzumab Ozogamicin, Multigated Acquisition Scan, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 70
States / cities: Birmingham, Alabama • La Jolla, California • Pembroke Pines, Florida + 60 more

Conditions: Advanced Solid Tumor, Malignant Solid Tumor
Interventions: Ifinatamab deruxtecan (I-DXd); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 10
States / cities: Denver, Colorado • Sarasota, Florida • Boston, Massachusetts + 6 more

Conditions: Breast Neoplasms, Breast Cancer
Interventions: Patritumab deruxtecan, Trastuzumab, Trastuzumab Biosimilar, Pertuzumab, Tucatinib; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Aurora, Colorado • Boston, Massachusetts • New Brunswick, New Jersey + 2 more

Conditions: Locally Advanced Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Unresectable Osteosarcoma
Interventions: Atezolizumab, Cabozantinib; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
Interventions: BCA101, Pembrolizumab; Drug
Lead sponsor: Bicara Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 10 more

Conditions: Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
Interventions: Radiation Therapy, Temozolomide, Veliparib; Radiation · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 25 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 145
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more

About this Dana-Farber Cancer Institute institution page

What this page lists: ClinicalTrials.gov records that list Dana-Farber Cancer Institute in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Dana-Farber Cancer Institute

Filter and sort this campus

Live official records

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

About this Dana-Farber Cancer Institute institution page